Capstone Therapeutics Corp. (NASDAQ:CAPS) Short Interest Down 45.4% in April

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the target of a significant decline in short interest in the month of April. As of April 15th, there was short interest totaling 73,622 shares, a decline of 45.4% from the March 31st total of 134,793 shares. Based on an average trading volume of 138,789 shares, the days-to-cover ratio is presently 0.5 days. Approximately 1.6% of the company’s shares are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Capstone Therapeutics stock. DRW Securities LLC acquired a new stake in Capstone Therapeutics Corp. (NASDAQ:CAPS) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned 1.51% of Capstone Therapeutics as of its most recent filing with the SEC. Institutional investors own 2.55% of the company’s stock.

Capstone Therapeutics Stock Down 5.7%

Capstone Therapeutics stock traded down $0.02 during trading hours on Wednesday, hitting $0.39. The company had a trading volume of 162,873 shares, compared to its average volume of 1,570,991. The firm has a market capitalization of $4.42 million, a P/E ratio of -0.11 and a beta of -1.27. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.00 and a quick ratio of 0.26. The firm’s fifty day moving average is $0.59 and its 200-day moving average is $0.74. Capstone Therapeutics has a fifty-two week low of $0.36 and a fifty-two week high of $3.29.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Capstone Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.